<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2522">
  <stage>Registered</stage>
  <submitdate>13/08/2009</submitdate>
  <approvaldate>13/08/2009</approvaldate>
  <nctid>NCT00991614</nctid>
  <trial_identification>
    <studytitle>EVOLUTION® Duodenal Stent for Duodenal or Gastric Outlet Obstruction Caused by Malignant Neoplasms</studytitle>
    <scientifictitle>Treatment of Duodenal or Gastric Outlet Obstruction and Duodenal Strictures Caused by Malignant Neoplasms With the EVOLUTION® Duodenal Stent</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>09-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Duodenal Obstruction</healthcondition>
    <healthcondition>Gastric Outlet Obstruction</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - EVOLUTION® Duodenal Stent

EVOLUTION® Duodenal Stent - 


Treatment: devices: EVOLUTION® Duodenal Stent
EVOLUTION® Duodenal Stent

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Patency of the stent</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural success, implant duration, symptom resolution</outcome>
      <timepoint>up to 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients for whom this device would be chosen in standard practice</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients for whom this device would not normally be chosen in standard practice</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>110</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Westmead Hospital - Sydney</hospital>
    <postcode>2145 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cook Group Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this investigation is to compile clinical experience on the use of the
      Evolution® Duodenal Stent (Cook Ireland), a CE marked device intended for the palliative
      treatment of duodenal or gastric outlet obstruction and duodenal strictures caused by
      malignant neoplasms. It is not the goal to change the usual treatment practice of the
      investigator or the center, nor to collect information on uses outside the product's
      indications. Patients will be treated as per usual medical practices.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00991614</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Guido Costamagna, MD</name>
      <address>U.O. Endoscopia Digestiva Chirurgica</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>